In Segment C, individuals will acquire ABBV-744 and oral navitoclax. In Phase D, members will receive ABBV-744 and ruxolitinib. Participants will receive treatment right up until disease progression or even the individuals are unable to tolerate the study drugs. - Participant consumed grapefruit or grapefruit products within 3 days previous https://chancewhtdl.fare-blog.com/32060425/clinical-trial-recruitment-for-abbv-744-study-fundamentals-explained